LymPro has previously been cited as a significant
Post# of 30028
Posted On: 01/04/2015 1:01:24 PM
LymPro has previously been cited as a significant cost savings and an aide to already established/expensive Dx image testings, such as CT, MRI or radioactive PET testings
question is - will it be accurate enough after tweaking to its greatest/highest use to reverse medical testing standards and eventually become a primary test candidate - now that would be something...
http://globenewswire.com/news-release/2014/10...AJZs5.dpuf
would also like to hear an update at the BioTech Conference on CPT codes and US billing through Medicare, Medicaid, and private practice medical insurers, as well as global marketing efforts reached thus far
question is - will it be accurate enough after tweaking to its greatest/highest use to reverse medical testing standards and eventually become a primary test candidate - now that would be something...
Quote:
"The company will make a final decision on which version of LymPro (Version 1 or Version 2) to launch under the CLIA designation, which will be marketed to the general population, following an in-depth analysis from the full cohort of 140 subjects. The company anticipates launching LymPro under CLIA shortly after product launch in the RUO marketplace."
http://globenewswire.com/news-release/2014/10...AJZs5.dpuf
would also like to hear an update at the BioTech Conference on CPT codes and US billing through Medicare, Medicaid, and private practice medical insurers, as well as global marketing efforts reached thus far
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼